Clinical trials: Parent Child Relationship
Parenting Practices, Self Efficacy
Evaluation Study of Talk Parenting Skills
After development of the prototype Bedtime Routine module of the Talk Parenting program, the investigators will evaluate its feasibility and initial efficacy in a within-subjects pre-post design study.
- Conditions
- Parenting Practices, Self Efficacy, Stress, Child Behavior
- Trial name
- NCT04633434
- Testing
- The Talk Parenting Skill for Alexa
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Oregon Research Behavioral Intervention Strategies, Inc.
Mumps
Special Drug Use Investigation for Botox® (Botulinum) Spasticity (BOTOX is a Registered Trademark of Allergan, Inc.)
The objective of this post-marketing surveillance study is to collect safety, efficacy and usage data on botulinum injection in subjects with upper or lower limb spasticity on the long-term use in clinical practice and to…
- Trial name
- NCT01390922
- Testing
- Botulinum Toxin Type A
- Volunteers
- 1,038 people
- Sponsor
- GlaxoSmithKline
Pancreatic Neoplasm, Digestive System Neoplasm
OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry.
The OSPREY Patient Registry has been developed to collect and assess the performance and safety of the OncoSil™ device when used within the approved indication of unresectable, locally advanced pancreatic cancer, in combination…
- Conditions
- Pancreatic Neoplasm, Digestive System Neoplasm, Neoplasms by Site, Neoplasms
- Trial name
- OSPREY (NCT04493632)
- Where
- 9 sites in Spain, United Kingdom
- Volunteers
- 500 people
- Sponsor
- OncoSil Medical Limited
Diabetes Mellitus, Type 2
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to semaglutide taken once a week in people with type 2 diabetes.
- Trial name
- COMBINE 2 (NCT05259033)
- Testing
- IcoSema, Semaglutide 1 mg
- Where
- 193 sites in United States, Brazil and 13 more
- Volunteers
- 683 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin icodec taken once a week in people with type 2 diabetes.
- Trial name
- COMBINE 1 (NCT05352815)
- Testing
- IcoSema, Insulin icodec
- Where
- 281 sites in United States, Australia and 20 more
- Volunteers
- 1,291 people
- Sponsor
- Novo Nordisk A/S
Advanced Solid Tumors
This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001
The purpose of this open-label, dose escalation-dose expansion, Phase 1 clinical trial is to evaluate the safety, pharmacokinetics and anti-tumor activity and determine the maximum tolerated dose (MTD) and recommended phase II…
- Trial name
- NCT03292783
- Testing
- NOV1501 (ABL001)
- Where
- 2 sites in South Korea
- Volunteers
- 45 people
- Sponsor
- ABL Bio, Inc.
Kidney Failure, Chronic
A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis
This is a multi-center, two-part study; Part A and Part B. Part A of the study is an open-label, single-dose pharmacokinetic (PK) evaluation of 100 mg RVX000222 on dialysis and non-dialysis days in eight (8) End Stage Renal…
- Trial name
- NCT03160430
- Testing
- apabetalone
- Volunteers
- 44 people
- Sponsor
- Resverlogix Corp
Healthy Subjects, Healthy Participant Study
This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of BEAM-103 in Healthy Subjects
The purpose of this Phase I single ascending dose study is to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of BEAM-103 in healthy subjects between the ages of 18 and 55.
- Trial name
- NCT07304791
- Testing
- BEAM-103
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Beam Therapeutics Inc.
Herpes Genitalis
A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.
Genital herpes (GH) is a commonly occurring sexually transmitted disease caused by herpes simplex virus (HSV). There are two types of HSV, type 1 (HSV-1) and type 2 (HSV-2); both can cause GH, although the latter is much more…
- Trial name
- NCT00158860
- Testing
- Valaciclovir
- Where
- 72 sites in United States, Argentina and 3 more
- Volunteers
- 384 people
- Sponsor
- GlaxoSmithKline
Other Preterm Infants
Invictus Medical, Medical Cranial Support Device (CSD) is a Device Safety Study in Infants at Risk of Head Ulcers.
While using the device as a cushion, the passive distribution of pressure over bony skull prominences of infants will protect against formation of pressure ulcers.
- Trial name
- INV-CS-001 (NCT02224859)
- Testing
- HCP will place the Invictus Cranial Support Device (CSD) on the patient, human intervention
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Invictus Medical, Inc.